The FDA has provided positive feedback regarding the PF614-MPAR development, acknowledging safety benefits and collaborative efforts.
9 reports, 1 independent
Updated Aug 31
Gone quiet
- Reports
- 9
- Developments
- 2
- Repetition
- 78%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA has provided positive feedback regarding the PF614-MPAR development, acknowledging safety benefits and collaborative efforts.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA gives positive feedback on Ensysce Biosciences' PF614-MPAR development.1 source
- PF614-MPAR earned Breakthrough Therapy designation, accelerating its clinical development.
Keep exploring
The entities involved
-
Ensysce Biosciences
company in La Jolla, United States
Nothing else this week.
- FDA
Related events
- FDA and Pfizer are seeking regulatory approval for their products.
- The FDA is monitoring product safety and manufacturing standards for Medisca Inc.
- FDA reviewed protocol amendment and interim safety data for a company's product.
- Annovis Bio discussed p-tau217 use with the FDA and plans to submit an NDA for review.
- FDA guidance is driving the need for a safety assessment related to issues in Rockville.
Coverage
Newest first; wire copies grouped- ACCESS NewswireEnsysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback ~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505
- Unknown outlet